
PivotalPath’s early October read shows the strain hit market-neutral funds too: the Equity Market Neutral Index fell 2.48%, its worst October on record. okt.to/rmMUd3

Daily institutional investing news from II magazine. Writing the inside story on all things asset management since 1967.

PivotalPath’s early October read shows the strain hit market-neutral funds too: the Equity Market Neutral Index fell 2.48%, its worst October on record. okt.to/rmMUd3

As inflation, resource constraints, and geopolitical fragmentation reshape markets, diversification assumptions are being put to the test. okt.to/3kG6cq Sponsored by @AspectCapital #InstitutionalInvesting #PortfolioConstruction #AssetAllocation

Only three companies are set to price this week, and all are health care names. The IPO market is still leaning on biopharma, even as investors wait for Anthropic later this month. okt.to/wrUigt

Research says the University of Illinois endowment could have been nearly $800 million larger. Leaders say the foundation has already overhauled the portfolio and are pressing that case now. okt.to/zW1X9l

Janus says the recent pullback in healthcare and biopharma could sharpen attention on fundamentals — and on entry points in high-quality biotech names. okt.to/Zts6ib

Marsh is buying Wilshire for its wealth advisory and alternatives capabilities, adding a broader institutional client base as advisory firms keep moving toward wealth and retail capital. okt.to/IOyXgJ

In Q3, global VC investment in robotics surged to $9.9 billion, more than double the previous year. This has led to 45 robotics firms achieving unicorn status in 2026 alone. What factors are driving this unprecedented growth? okt.to/mFyxq9

In October, market-neutral funds faced unexpected challenges, with the Equity Market Neutral Index dropping 2.48%, marking its worst October on record. What does this mean for future hedge fund strategies? okt.to/nXSrPA

Three IPOs are set to price this week, and all are health care-related. Biopharma is still carrying the IPO market, but the bigger question is how long that can last for allocators. okt.to/n8SkDP

Hedge funds often face criticism for high fees and underperformance, but a critical gap in data reporting is complicating investors' evaluations. How this missing data skews perceptions—and what it means for asset allocators—remains an open question. okt.to/LwtyMR

The University of Illinois Foundation is defending a portfolio overhaul after research said the $3.3 billion endowment could have been nearly $800 million larger. The question is whether the reset is enough. okt.to/IVlz4t

Chris Hohn's TCI Fund Management recorded a small gain in October but remains down 2% for the year, raising questions about its recovery trajectory after a record 2025 with nearly $19 billion in profits. What does this mean for investors? okt.to/xq0Ov4

Following the Democratic sweep, J.P. Morgan's Michael Cembalest highlights that almost all major local ballot measures against data centers have succeeded, raising concerns over future growth in the sector. What implications could this have for investors? okt.to/lsrC4U

Third Point has sharply reduced risk, cutting semiconductor, data center-adjacent, and hyperscaler exposure. Dan Loeb appears willing to miss the first leg of a rally rather than race back into tech. okt.to/tPbEcB

Many of the largest hedge funds are missing from the databases institutions use to judge the industry. What are allocators measuring when they decide whether hedge funds are worth it? okt.to/WqP3DO

As AI investments in emerging markets surge, other sectors, particularly financials, are being overlooked. Mark Headley of Matthews highlights that while there are opportunities, "patience and a strong stomach are required." okt.to/flMcaj